{
 "context": "The following article called 'Novartis acquires all remaining rights to GSK's Ofatumumab to develop treatments for MS and other autoimmune indications' was published on 2015-08-21. The body of the article is as follows:\n    \nNovartis AG 21/08/2015 | Press release Novartis acquires all remaining rights to GSK's Ofatumumab to develop treatments for MS and other autoimmune indications \ndistributed by noodls on 21/08/2015 05:51\n\n    The day before the article was published, the stock price of Novartis AG was 72.6113510131836 and the day after the article was published, the stock price of Novartis AG was ",
 "expected": "68.39823150634766",
 "date": "2015-08-21",
 "ticker": "NVS",
 "company": "Novartis AG"
}